Home

Treatment

Read time: 3 min

Does glutamate hold the key to unlocking major depressive disorder?

Despite over 50 years of drug development in major depressive disorder (MDD), patients and their...

Read time: 3 min

Congress highlights

Transforming healthcare — the changing landscape of patient engagement

Patient engagement is the facilitation and strengthening of the role of patients as co-producers of...

Read time: 3 min

Congress highlights

Early dialogues with patients are informing medicines development

A 200-strong audience of health economics and outcomes research professionals at ISPOR 2018...

Parkinson's Disease

Read time: 3 min

New therapeutic technologies and targets for Parkinson’s disease

A gastroretentive capsule containing multiple layers of biodegradable film, intraoral infusion via...

Read time: 5 min

Managing the burdens of bipolar disorder

The cognitive and physiological burdens of bipolar disorder, and some approaches to its treatment,...

Alzheimer's Disease

Read time: 3 min

Congress highlights

A complete solution for patients with Alzheimer’s disease may be on the horizon

New treatments and improved diagnostic and staging tools will allow for a complete solution for...

Alzheimer's Disease

Read time: 2 min

Congress highlights

Active immunotherapy targets early stage Alzheimer’s disease

Active immunotherapies have been designed to activate an immune response in the human body of...

Alzheimer's Disease

Read time: 3 min

Congress highlights

Initial promise of immunotherapeutics targeting amyloid-β strengthens the possibility of early intervention in Alzheimer’s disease

Clinical studies of immunotherapies show initial promise for early intervention in Alzheimer’...

Alzheimer's Disease

Read time: 3 min

Congress highlights

The many faces of tau offer multiple targets for intervention in Alzheimer’s disease

Tau is a complex, multifaceted target, implicated in many mechanisms involved in the pathology of...

Read time: 3 min

Future of schizophrenia treatment: Where do we go now?

Over the next decade, the outcomes for patients with schizophrenia should improve considerably,...

Read time: 5 min

Congress highlights

Severity and Treatment of Depression: A Review of Two Controversies

Antidepressants are not limited to severely depressed patients, and psychotherapy is not limited to...

Read time: 3 min

Innovation and tailored treatments drive improved outcomes in depression

We are a step closer to the early detection of antidepressant treatment failure, a paradigm shift...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country